Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026

Phase 2positiveleniolisibPositive

AI Analysis

Summary

Pharming announced positive Phase 2 topline data for leniolisib in patients with primary immunodeficiencies with immune dysregulation, with the results accepted as a late-breaking abstract at ESID 2026.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

positive Phase II topline data accepted as late-breaking abstract at ESID 2026

Importance:7/10

Sentiment:

0.80

Phase 2positive dataleniolisibPIDsimmune dysregulationESID 2026

Related Companies

$PHAR

Read the original article

Published by yahoo_finance on September 22, 2026 5:00 AM

Read Original